Acute Dosing of MK-8892 in Participants With Pulmonary Arterial Hypertension (PAH) (MK-8892-003)

This study has been terminated.
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp. Identifier:
First received: August 30, 2013
Last updated: December 2, 2014
Last verified: December 2014
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: September 2014
  Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)